2017 Satellite Meeting

Drug Discovery for Ion Channels XVII

Friday, February 10, 8:00 AM - 5:00 PM
New Orleans Ernest N. Morial Convention Center, Room 210

Pre-Registration is closed.  Registration will be accepted on-site.

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. For this year, we propose to continue the “Satellite Meeting” tradition at the Biophysical Society Annual Meeting to review the advances in automated electrophysiology and other emerging technologies and their impact on ion channel drug discovery. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers. 


Agenda

 8:00 AM - 8:30 AMRegistration and Coffee 
 8:30 AM - 8:45 AMChris Mathes, Icagen Inc
Welcome and Opening Remarks
 8:45 AM - 9:30 AMKeynote Speaker: Stephen J. Tucker, University of Oxford, United Kingdom
New Insights into K2P Potassium Channel Biophysics
 Session I: Anion Channels, Chair: Chris Mathes, Icagen Inc
 9:30 AM - 10:00 AMMerritt Maduke, Stanford University
Strategies for Developing Isoform-specific CLC Chloride-channel Inhibitors
  Session II: Na Channels & Pain, Chair: Andrew Baxter, Charles River
 10:00 AM - 10:30 AMRamkumar Rajamani, Bristol-Myers Squibb
Targeting NaV1.7 channels: Opportunities and Challenges
 10:30 AM - 11:00 AMCoffee Break
 11:00 AM - 11:30 AMNeil Castle, Icagen, Inc
Overcoming Challenges of Targeting Nav1.9 for Development of New Pain Therapies
 11:30 AM - 12:00 PM        Jun Chen, Genentech
Discovery of novel Nav1.7 scaffolds
 12:00 PM - 12:30 PMDavid Hackos, Genentech
Selective Inhibitors of Nav1.7: From Binding Site to in-vivo Efficacy
 12:30 PM - 1:30 PMLunch
 Session III: Ion Channels and Disease, Chair: Richard Kondo, Sophion - Biolin Scientific
 1:30 PM - 2:00 PMJen Pan, Broad Institute
High Throughput Electrophysiology to Annotate Channel Functions in the Context of Disease Genetics
 2:00 PM – 2:30 PMAamir Ahmed, King's College London, United Kingdom
Drug Discovery for Cancer Therapy: a Combination of High Throughput Electrophysiology and Live Cell and Calcium Imaging
 2:30 PM - 3:00 PMJohn McCafferty, IONTAS, United Kingdom
Generating Ion Channel Blocking Antibodies by Fusing Cysteine-knot Miniproteins into Antibody CDR Loops

 3:00 PM - 3:30 PMCoffee Break
 Session IV: Regulation of Ion Channels, Chair: Jeff Webber, Molecualr Devices LLC
 3:30 PM – 4:00 PMDiomedes Logothetis, Virginia Commonwealth University
Allosteric Modulators of Channel-PIP2 Interactions
 4:00 PM - 4:30 PMZhao-Wen Wang, University of Connecticut
Antidromic-rectifying Gap Junctions Amplify Chemical Transmission from Premotor Interneurons to Motoneurons
 4:30 PM - 5:00 PMSarah Lilley, Sussex Drug Discovery Centre, Sussex University
TMEM16A: High-throughput Functional Screening Approaches to a Novel Therapeutic Target
 5:00 PMNiels Fertig, Nanion Technologies GMBH, Germany
Closing Remarks

Sponsored by: